1Hohn I, Sclhweizer A, Morel DR,et al. Circulatory failure afteranesthes in induction in a patient with sevsre primary hyperten- sion [J].Anesthesiology, 1999,91 (6) - 1943-1945.
3Tight blood pressure controland risk of macrovaseular and microvascu- lar complications in type 2 diabetes: UKPDS38. UK Prospective Dia- betes Study Group [J]. BMJ,1998,317(7160) :703-713.
1Muscelli E,Casolaro A,Gastaldelli A,et al. Mechanisms forthe antihyperglycemic effect of sitagliptin in patients with type 2 diabe-tes. J Clin Endocrinol Metab 2012;97(8) :2818-2826.
2Lotfy M, Singh J, Kaldsz H, et al. Medicinal chemistry and ap-plications of incretins and DPP-4 inhibitors in the treatment of type 2diabetes mellitus. Open Med Chem J 2011 ;5( Suppl 2) :82-92.
3Takeda Y,Fujita Y, Honjo J, et al. Reduction of both beta celldeath and alpha cell proliferation by dipeptidyl peptidase-4 inhibition ina streptozotocin-induced model of diabetes in mice. Diabetologia2012;55(2) :304412.
4Hong ES, Khang AR, Yoon JW, et al. Comparison betweensitagliptin as add-on therapy to insulin and insulin dose-increase thera-py in uncontrolled Korean type 2 diabetes : CSI study. Diabetes ObesMetab 2012;14(9) :795-802.
5Del Prato S, Marchetti P. Beta-and alpha-cell dysfunction intype 2 diabetes. Horm Metab Res 2004 ;36( 11-12) :775-781.
